Dry Age-related Macular Degeneration
Dry Age-related Macular Degeneration (Dry AMD), also called atrophic AMD, is the most common form of Age-related Macular Degeneration. It is caused due to the appearance of small yellowish deposits called drusen under the eye's retina.
Currently, the Dry Age-related Macular Degeneration domain comprises a highly robust pipeline with more than 40 drugs under different phases of development. Although there are many drugs in various stages of clinical trials, there's still no curative treatment for Dry Age-related Macular Degeneration as of now.
Learn more about Dry Age-related Macular Degeneration, its causes, symptoms, diagnosis, and available treatments through our newsletter. It brings to you rich insights into Dry AMD marketed therapies as well as emerging Dry AMD pipeline therapies, epidemiological statistics, and key companies operating the Dry AMD market.
DelveInsight's Dry Age-related Macular Degeneration newsletter covers the recent news and happenings in the Dry AMD therapeutics market domain, ongoing clinical trials, drugs approvals, novel drug launches, prevailing unmet needs, market dynamics shaping the Dry Age-related Macular Degeneration market landscape, mergers and collaborations, licensing deals, and top conferences occurring in the Dry AMD therapy market domain.
Subscribe to our mailing list and stay informed about all the recent breakthroughs in the Age-related Macular Degeneration market.
Track recent updates in the Dry Age-related Macular Degeneration domain by downloading our newsletter; simply fill the form towards the right and stay in touch to learn more about our offerings and services.
Know more about What's covered:
- Indication overview
- Signs, symptoms, and diagnosis
- Epidemiological trends
- Treatment approaches
- R&D in the field
- Top conferences
- News flash
- Recent Research Activities
- Support from International organizations
- Market insights
- Dry Age-related Macular Degeneration Market Dynamics
- Collaborations and deals in the domain
